Designed for operation in harsh and difficult conditions, the PulmO2 brings oxygen therapy to millions in underserved regions
Port Washington, NY – Drive DeVilbiss Healthcare (DDH), a global leader in respiratory care, proudly launches the PulmO2 Oxygen Concentrator, an innovative solution to improve access to oxygen therapy in low- and middle-income countries (LMICs). With over a million preventable deaths annually from hypoxemia in these regions, the PulmO2 addresses a critical gap in healthcare.
The PulmO2’s advanced features make it highly effective in resource-limited settings:
The PulmO2 represents DDH’s longstanding commitment to healthcare innovation, developed through extensive research and testing. To ensure effective delivery and operation, the company collaborated with Sanrai International, a key partner experienced in bringing medical equipment to underserved regions, to tap into the intricacies of underserved regions and ensure the concentrator’s effectiveness in the most challenging settings.
Through this partnership, the PulmO2 launches as part of a broader initiative that includes education, training, and advocacy for sustainable healthcare solutions.
“Our mission has always been to lead in creating innovative healthcare solutions that improve lives,” said DDH CEO Derek Lampert. “The PulmO2 is a testament to our commitment to transforming challenging healthcare environments. We are proud to partner with Sanrai to ensure that no patient, regardless of location, is left without access to critically important oxygen.”
DDH and Sanrai invite healthcare professionals, policymakers, and global partners to join in making oxygen accessible for all. For more information, visit https://pulmo2-concentrator.com or contact info@pulmo2-concentrator.com.